WO2022167867 - SUBSTITUTED CYCLIC MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME
National phase entry:
Publication Number
WO/2022/167867
Publication Date
11.08.2022
International Application No.
PCT/IB2022/000060
International Filing Date
07.02.2022
Title **
[English]
SUBSTITUTED CYCLIC MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME
[French]
MODULATEURS CYCLIQUES SUBSTITUÉS DE PROTÉINE PHOSPHATASE 2A (PP2A) ET LEURS PROCÉDÉS D'UTILISATION
Applicants **
RAPPTA THERAPEUTICS OY
Haartmaninkatu 4
Terkko Health Hub
00290 Helsinki, FI
Inventors
TRAINOR, George, L.
9 Carillon Court
Wilmington, DE 19803, US
RABAL GRACIA, Maria, Obdulia
C/Deportes 2
Peralta de Alcofea
Huesca 22130, ES
FOURMOIS, Laura
6 Rue Romain Gary
78180 Montigny Le Bretonneux, FR
GHERBOVET, Olga
9 Rue Occitanie
31410 Saint-Hilaire, FR
CACHOUX, Frederic
3 Clos Saint-jammes
31460 Caraman, FR
Priority Data
63/273,405
29.10.2021
US
63/191,405
21.05.2021
US
63/146,789
08.02.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 11272 | |
| EPO | Filing, Examination | 261685 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 640 | |
| USA | Filing, Examination | 65360 |
Total: 339548 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure relates in part to chemical modulators of protein phosphatase 2A (PP2A). The compounds of the present disclosure are useful in treating, preventing, and/or ameliorating cancer, diabetes, autoimmune disease, solid organ transplant rejection, graft vs host disease, chronic obstructive pulmonary disease (COPD), non-alcoholic fatty liver disease, abdominal aortic aneurysm, chronic liver disease, heart failure, neurodegenerative disease, and cardiac hypertrophy.[French]
La présente divulgation concerne en partie des modulateurs chimiques de la protéine phosphatase 2A (PP2A). Les composés selon la présente divulgation sont utiles dans le traitement, la prévention et/ou le soulagement du cancer, du diabète, de maladies auto-immunes, du rejet de greffe d'organe solide, de la maladie du greffon contre l'hôte, de la broncho-pneumopathie chronique obstructive (BPCO), la stéatose hépatique non alcoolique, l'anévrisme aortique abdominal, une maladie hépatique chronique, une insuffisance cardiaque, une maladie neurodégénérative et une hypertrophie cardiaque.